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Bacteroides fragilis group (BFG) are the most frequently recovered anaerobic
bacteria from human infections, and resistance to frontline antibiotics is emerging. In the
absence of routine antimicrobial susceptibility testing (AST) for BFG in most clinical settings,
we assessed the utility of clinical and modern genomics tools to determine BFG specieslevel identiﬁcation and resistance patterns. A total of 174 BFG clinical isolates supplemented
with 20 archived carbapenem-resistant B. fragilis sensu stricto (BFSS) isolates underwent
antimicrobial susceptibility testing, MALDI-ToF mass-spectrometry, and whole-genome
sequencing (WGS). Bruker BioTyper and VITEK-MS MALDI-ToF systems demonstrated
accurate species-level identiﬁcations (91% and 90% agreement, respectively) compared
to average nucleotide identity (ANI) analysis of WGS data. Distinct b -lactamase gene
proﬁles were observed between BFSS and non-fragilis Bacteroides species, with signiﬁcantly higher MICs to piperacillin-tazobactam in B. vulgatus and B. thetaiotaomicron relative to BFSS (P # 0.034). We also uncovered phylogenetic diversity at the genomospecies level between division I and division II BFSS (ANI ,0.95) and demonstrate that
division II BFSS strains harbor an increased capacity to achieve carbapenem resistance
through chromosomal activation of the CﬁA carbapenemase. Finally, we report that CﬁA
detection by the Bruker BioTyper Subtyping Module accurately detected carbapenem resistance in BFSS with positive and negative percent agreement of 94%/90% and 95%/
95% compared to ertapenem and meropenem susceptibility, respectively. These comparative analyses indicate that resistance mechanisms are distinct at both the phenotypic
and genomic level across species within the BFG and that modern MALDI-ToF identiﬁcation systems can be used for accurate species-level identiﬁcation and resistance prediction of the BFG.
IMPORTANCE Anaerobic infections present unique challenges in terms of detecting
and identifying the etiologic agent and selecting the optimal antimicrobial therapy.
Antimicrobial resistance is increasing in anaerobic pathogens, and it is critical to
understand the prevalence and mechanisms of resistance to commonly prescribed
antimicrobial therapies. This study uses comparative genomics to validate clinical
tools for species-level identiﬁcation and phenotypic resistance prediction in 194 isolates of Bacteroides fragilis group (BFG) bacteria, which represent the most commonly
isolated organisms among anaerobic infections. We demonstrate species-speciﬁc patterns in antimicrobial resistance and validate new strategies for species-level
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organism identiﬁcation and phenotypic resistance prediction in a routine clinical laboratory setting. These ﬁndings expand our understanding and management of anaerobic infections and justify further investigations into the molecular basis for species-speciﬁc resistance patterns observed within this study.
KEYWORDS Bacteroides, anaerobes, antibiotic resistance, beta-lactams, carbapenems,

genomics, mass spectrometry, taxonomy
he diagnosis and treatment of anaerobic infections pose several unique challenges.
These infections are often polymicrobial and caused by an array of species that can
be slow-growing or difﬁcult to cultivate and require specialized specimen collection
techniques (1). Bacteroides fragilis group (BFG) species are the most frequently isolated
organisms from anaerobic infections and can be recovered from various sites, including abscesses and bloodstream infections (2). A common source of anaerobic infection
is the commensal microbiota, of which Bacteroides and Parabacteroides are found in
high abundance in the gastrointestinal tract of healthy humans (3).
Increases in the incidence of anaerobic infection have been observed in recent
years (4), and antimicrobial resistance is associated with increased morbidity and mortality (5). Most clinical laboratories do not perform antimicrobial susceptibility testing
for anaerobic bacteria. Infections with BFG are typically treated empirically with agents
such as metronidazole, b -lactam/ b -lactamase inhibitor combinations, or carbapenems
(6). However, resistance to b -lactam/ b -lactamase inhibitor combinations and carbapenems is emerging in BFG organisms, and resistance to metronidazole and other antibiotic classes have also been described (7–10). Antibiotic susceptibility surveys have suggested species-speciﬁc trends in phenotypic resistance among BFG organisms (8).
Furthermore, B. fragilis sensu stricto (BFSS) is most associated with carbapenem resistance and can be categorized into two divisions based on the absence (division I) or
presence (division II) of the chromosomally encoded carbapenemase gene, cﬁA (11).
Large-scale genomic studies are lacking for BFG bacteria, which could validate the accuracy of clinical tools routinely used to identify members of BFG to the species level.
Furthermore, comparative resistome studies within a large and taxonomically diverse
collection of BFG bacteria could inform distinct resistance mechanisms underlying previously observed species-dependent resistance proﬁles.
Here, we present a comprehensive clinical and comparative genomics study of a
collection of 174 BFG isolates collected in St. Louis, MO from 2018 to 2020, supplemented with 20 carbapenem-resistant BFSS isolates. We performed species-level identiﬁcation, phenotypic susceptibility testing, and whole-genome sequencing (WGS) on
this collection of isolates. Matrix-assisted laser desorption ionization time of ﬂight mass
spectrometry (MALDI-ToF) species-level identiﬁcations were conﬁrmed using comparative genomics. We report distinct phenotypic and genotypic resistance proﬁles among
BFG species against frontline antibiotic agents, bolstering the value of routine specieslevel reporting of BFG in clinical practice. Finally, we analyzed annotated antibiotic resistance genes (ARGs) against relevant antibiotics in this isolate collection and
expanded the characterization of the genetic distinction between division I and division II BFSS. Our data evaluated the reliability of several clinical tools to accurately
determine both BFG species and resistance proﬁles while providing a comprehensive
landscape of the antibiotic resistome in BFG with special attention toward commonly
utilized anaerobic treatment options.
RESULTS
Comparison of WGS and MALDI-TOF MS characterization of BFG isolates. A total
of 174 BFG isolates recovered from patient samples submitted to the Barnes-Jewish
Hospital in St. Louis, Missouri from 2018 to 2020 during routine clinical care were evaluated in this study (Fig. 1, see Materials and Methods). Isolates were recovered from a
variety of sources that were grouped into 4 categories: 1, wound, ﬂuid, abscess, or
drainage from abdominal sites (n = 50); 2, wound or abscess from non-abdominal sites
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(n = 60); 3, tissue or aspirate from non-abdominal sites (n = 36); 4, blood, bone, and
bone marrow (n = 26) (Data Set S1). MALDI-TOF MS analysis was performed on all isolates using the Bruker BioTyper (Billerica, MA) and bioMérieux VITEK-MS (Durham, NC)
(Data Set S1). Among the isolates, 9 unique BFG species were isolated representing
both Bacteroides and Parabacteroides genera (Fig. 1). Most isolates analyzed were from
wounds and abscesses from both abdominal and non-abdominal sites (Fig. 1). The distribution of BFG species was similar between isolate source groupings with approximately half of the isolates identiﬁed as BFSS (n = 83), followed by B. vulgatus (n = 30),
B. thetaiotaomicron (n = 24), B. ovatus (n = 18), and P. distasonis (n = 11).
BFG bacteria are taxonomically diverse, consisting of at least 24 species from two
distinct families (Bacteroidaceae and Tannerellaceae) (2). To conﬁrm the accuracy of
species-level identiﬁcation of the Bruker BioTyper and VITEK-MS platforms, we performed Illumina short-read WGS of the entire isolate collection. De novo assemblies
were generated from the WGS data (see Materials and Methods and Fig. S1) and used
to perform phylogenomic analyses, which were compared directly with MALDI-ToF
identiﬁcations (Fig. 2). On a phylogenetic tree generated from a core genome alignment of isolate and type BFG assemblies, each isolate clustered with type assemblies

FIG 2 Taxonomic analysis of the BFG isolate collection from Barnes-Jewish Hospital. (A) Phylogenetic tree of complete BFG isolate collection generated
from core genome alignment with type assemblies. (B) Species-level identiﬁcations determined by two commonly utilized MALDI-ToF technologies. (C)
Pairwise average nucleotide identity (ANI) and pairwise average amino acid identity (D) values for the BJH isolates compared with type assemblies. *ANI
values for isolate pairs with percentage identity .0.85 that did not have adequate genome coverage (coverage ,0.5) following pyani analysis were
excluded.
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FIG 1 Infection sources and species distribution of 174 B. fragilis group (BFG) isolates collected from patient
specimens submitted to the Barnes-Jewish Hospital in St. Louis, Missouri. Species data from Bruker Biotyper
MALDI-ToF MS are shown.
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matching most of the Bruker isolate identiﬁcations and VITEK-MS identiﬁcations.
Exceptions included ﬁve BFSS isolates forming a clade independent of the BFSS type
assembly as well as two isolates exhibiting discordant species identiﬁcations between
the two MALDI-ToF systems: BJH_3 (Bruker: B. faecis, VITEK-MS: B. thetaiotaomicron)
and BJH_39 (Bruker: B. ovatus, VITEK-MS: B. thetaiotaomicron). BJH_3 formed a clade
with a B. faecis type assembly and shared .95% average nucleotide identity (ANI) with
this assembly. Furthermore, by the same metric BJH_39 appeared to be B. ovatus.
B. ovatus, B. faecis, and B. thetaiotaomicron reside in adjacent clades in the phylogenetic tree (Fig. 2), which may explain the discordant identiﬁcations within these species
(12). Further exceptions were represented by two strains identiﬁed as B. ovatus by
both Bruker and VITEK but shared 98% ANI with a B. xylanisolvens type assembly in
contrast to only sharing 94% ANI with a B. ovatus type assembly (Fig. 2). Additionally,
eight isolates originally identiﬁed as B. vulgatus had a higher pairwise ANI with a B.
dorei type assembly and formed a distinct clade. However, the ANI threshold for the
species-level identity of each of these eight isolates was met with each strain respective to type assemblies from both B. vulgatus and B. dorei species (ANI .95%) (Fig. S2)
(12). Altogether, the percentage agreement between MALDI-ToF species callout and
species determination via ANI was 91% (159/174) for Bruker and 90% (156/174) for
VITEK-MS. The ﬁve BFSS isolates forming a distinct clade exhibited ANI within the range
of 0.85 to 0.90 relative to the BFSS type assembly GCF_000025985. All isolates had
.60% average amino acid identity (AAI) with the respective type assemblies, the meeting proposed genus-level AAI cutoffs (13, 14) within Bacteroides or Parabacteroides.
Antimicrobial resistance proﬁles are distinct across BFG species. Susceptibility
testing was performed using gradient diffusion for four commonly prescribed anaerobic
agents, including metronidazole, piperacillin-tazobactam, meropenem, and ertapenem (Fig. 3
and Table 1). Carbapenem resistance was detected but uncommon in our collection; however,
increased carbapenem resistance among BFSS has been reported (7). Our clinical isolates
were supplemented with a collection of BFSS strains enriched for carbapenem resistance from
the IHMA strain bank (Data Set S1). Statistical differences in the mean MIC between all species
groups were calculated using ordinary one-way ANOVA with Tukey’s multiple-comparison
test to compare each species group. Geometric mean metronidazole MIC values did not signiﬁcantly differ between all species (P $0.2207) (Fig. 3A). However, MICs to b -lactam antibiotics were uniformly elevated in non-fragilis Bacteroides species relative to BFSS (Fig. 3B to D).
The piperacillin-tazobactam MICs were signiﬁcantly elevated for B. thetaiotaomicron isolates
(P = 0.005; MIC50 = 16, MIC90 = 256 m g/mL), followed by B. ovatus (MIC50 = 16, MIC90 = 32 m g/
mL) and B. vulgatus (MIC50 = 8, MIC90 = 256 m g/mL) (P = 0.0338), suggesting that b -lactam resistance is more common among non-fragilis species. Non-susceptibility to any b -lactam
agent tested was rare among BFSS BJH isolates, and, as expected, IHMA isolates were mostly
ertapenem (MIC50 = 16, MIC90 . 32 m g/mL), meropenem (MIC50/90 . 32 m g/mL), and piperacillin-tazobactam resistant (MIC50 = 64, MIC90 . 256 m g/mL) (Table 1).
To identify potential mechanisms of resistance, AMRﬁnder (15) was employed to interrogate the ARG proﬁle of these strains (Fig. 4 and Fig. S3). A collection of previously
reported commensal BFSS assemblies from 12 individuals was also included to understand the baseline ARG proﬁle of this species (16). All 205 BFG genomes encoded a
rich population of ARGs against multiple classes, including tetracyclines, macrolides,
and b -lactams (Fig. S3A). Distinct b -lactamase distribution patterns were observed
among BFSS, non-fragilis Bacteroides species, and Parabacteroides species (Fig. 4). BFSS
isolates exclusively harbored either the cepA or cﬁA gene, which indicates the categorization of each strain as division I (cepA1/cﬁA-) or division II (cepA-/cﬁA1) (Fig. 4A and
B) (11). The representative commensal BFSS genomes only encoded the cepA b -lactamase gene. In contrast, clinical non-fragilis Bacteroides isolates were enriched for class
A b -lactamase genes identiﬁed through the Hidden Markov Model (HMM) proﬁling
function of AMRﬁnder (bla genes, Fig. 4C). These bla genes shared $27.3% amino acid
identity and formed approximate species-speciﬁc clusters, with a closely related multispecies clade also observed (Fig. S4). Cefoxitin resistance genes, cfx, were abundant in
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FIG 3 Scatterplot of MICs of BJH isolates to select antibiotic agents: (A) Metronidazole. (B) Piperacillin-Tazobactam. (C) Ertapenem. (D) Meropenem. Green,
yellow, and red regions represent susceptible, intermediate, and resistant interpretations, respectively, according to CLSI guidelines (34). Dashed lines
represent EUCAST clinical breakpoints (35). Geometric mean and 95% conﬁdence interval are plotted with statistically signiﬁcant adjusted P values (P ,
0.05) shown. Statistical analysis was performed using ordinary one-way ANOVA with Tukey’s multiple-comparison test to compare the means of each
species group using Prism v9.0.0. Species groupings for the isolates are based on average nucleotide identities relative to type genomes.

major non-fragilis BFG species (B. vulgatus, B. thetaiotaomicron, and B. ovatus), and
were enriched in BFSS with elevated b -lactam resistance. For BFSS, phenotypic carbapenem resistance was only observed in the presence of the cﬁA gene, except for
IHMA_8 which had both cepA and an HMM-identiﬁed bla gene conserved among multiple species (Fig. 4A and B, Fig. S4A). Among all BFG isolates, a higher total number of
b -lactamases was often associated with increased MICs to piperacillin-tazobactam
(Fig. 4), especially in the case of cfx-positive BFSS strains (Fig. 4A and B).
Insertion sequences activate cﬁA-mediated carbapenem resistance in B. fragilis
SS. The presence of the cﬁA gene alone does not typically correspond to high-level carbapenem resistance in BFSS due to inefﬁcient gene expression from the native promoter (17).
However, insertion sequences (IS) upstream of the gene can increase cﬁA expression and
result in high-level carbapenem resistance (10, 17). To identify the mechanism of carbapenem resistance in this cohort and validate available tools to determine phenotypic resistance, we compared genomic cﬁA and upstream IS identiﬁcations with the Bruker MALDI
Biotyper Subtyping module (MBT-S) and previously reported PCR-based screening methods
that detect both cﬁA and associated ISs (18).
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98
68
13
44
100
61
100
0
100
100

MIC90
0.5
1
0.5
16
1
2
0.25
2
N/A
0.5

CLSI-%S
98
100
96
88
100
100
100
100
100
100

EU-%S
94
82
96
75
82
89
100
50
100
100

MIC50
0.125
0.25
0.25
0.5
0.125
0.25
0.125
0.25
NA
0.25

MIC90
0.5
1
0.5
32
1
2
0.125
1
N/A
0.5

CLSI-%S
98
100
96
88
100
100
100
100
100
100

Meropenem
CLSI: S, MIC £4 mg/mL
EUCAST: S, MIC £2 mg/mL

CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Union Committee on Antimicrobial Susceptibility Testing; S, susceptible.
dorei (n = 8), B. caccae (n = 3), B. faecis (n = 2), B. xylanisolvens (n = 2), B. pyogenes (n = 1), P. merdae (n = 2).

CLSI-%S
98
77
50
56
100
83
100
0
100
100

MIC50
0.125
0.25
0.5
0.5
0.25
0.25
0.25
0.5
NA
0.25

MIC90
4
256
256
256
0.5
256
8
256
N/A
4

MIC50
1
8
16
16
0.25
8
8
32
NA
4
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aAbbreviations:

B. fragilis (n = 83)
B. vulgatus (n = 22)
B. thetaiotaomicron (n = 24)
B. ovatus (n = 16)
Parabacteroides distasonis (n = 11)
Other Bacteroides fragilis groupb (n = 18)
B. caccae (n = 3)
B. faecis (n = 2)
B. pyogenes (n = 1)
P. merdae (n = 2)

Ertapenem
CLSI: S, MIC £4 mg/mL
EUCAST: S, MIC £0.5 mg/mL

Piperacillin/tazobactam
CLSIa: S, MIC £16 mg/mL
EUCAST: S, MIC £8 mg/mL

TABLE 1 Antimicrobial susceptibility data for Bacteroides fragilis group isolates collected at the Barnes-Jewish Hospital in St. Louis, MO

EU-%S
98
100
96
88
100
100
100
100
100
100

MIC50
0.25
0.125
0.25
0.25
0.25
0.125
0.25
0.032
NA
0.25

MIC90
0.5
1
0.5
0.5
0.5
0.25
0.25
0.25
N/A
0.25

CLSI-%S
100
95
100
100
100
100
100
100
100
100

Metronidazole
CLSI: S, MIC £8 mg/mL
EUCAST: S, MIC £4 mg/mL
EU-%S
100
91
100
100
100
100
100
100
100
100
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FIG 4 Phenotypic and genotypic resistance to b -lactam classes for (A) BFSS IHMA isolates and representative commensal BFSS genomes (16), (B) BFSS isolates
collected at Barnes-Jewish Hospital (BJH) in St. Louis, MO, and (C) non-BFSS BFG isolates also collected at BJH. Isolates are ordered by their phenotypic resistance
proﬁle to piperacillin-tazobactam; AST bars are colored based on the CLSI interpretations (34) with dashed lines representing EUCAST breakpoints (35).
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TABLE 2 CﬁA carbapenemase and associated insertion sequence detection in B. fragilis sensu stricto isolates with phenotypic or genotypic
carbapenem resistance determinants

Strain
BJH_13
BJH_14
BJH_140
BJH_141
BJH_220
IHMA_1
IHMA_2
IHMA_3
IHMA_4
IHMA_5
IHMA_6
IHMA_7
IHMA_8
IHMA_9
IHMA_10
IHMA_11
IHMA_12
IHMA_13
IHMA_14
IHMA_15
IHMA_16
IHMA_17
IHMA_18
IHMA_19
IHMA_20

72 h MIC (mg/mL)

cﬁA detection

Ertapenem
.32
.32
0.5
0.5
0.5
.32
4
.32
32
8
.32
8
16
1
.32
8
1
2
1
2
.32
16
.32
.32
.32

MALDI
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1

Meropenem
.32
.32
1
1
1
.32
.32
.32
.32
32
.32
.32
.32
4
.32
.32
8
32
8
16
.32
.32
.32
.32
.32

PCR
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1

IS detection
AMRFinder
cﬁA2
cﬁA2
cﬁA
cﬁA
cﬁA
cﬁA4
cﬁA2
cﬁA13
cﬁA2
cﬁA2
cﬁA14
cﬁA14
2
cﬁA14
cﬁA
cﬁA2
cﬁA
cﬁA
cﬁA13
cﬁA2
cﬁA13
cﬁA4
cﬁA13
cﬁA17
cﬁA17

PCR
1
1
2
2
2
1
2
1
1
2
1
2
2
2
1
2
2
2
2
2
2
1
1
1
1

ISﬁnder
IS612B
IS612B
Partial ISBf9
Partial ISBf9
2
IS613
None detected
IS942
IS1169
2
IS616
2
2
Partial ISBf9
IS982#
2
2
2
2
2
IS614B
IS4351
IS614
ISBf11
ISBf11

Family
IS1380
IS1380
2
2
2
IS1380

Identities
1595/1596
1595/1596
2
2
2
1595/1595

Origin
Bacteroides fragilis
Bacteroides fragilis
2
2
2
Bacteroides fragilis

IS1380
IS5
2
IS1380
2
2
2
IS982
2
2
2
2
2
IS1380
IS30
IS1380
IS1380
IS1380

1592/1598
1301/1317
2
1691/1691
2
2
2
2
2
2
2
2
2
1532/1597
1155/1155
1585/1596
1457/1594
1457/1594

Bacteroides fragilis
Bacteroides fragilis
2
Bacteroides fragilis
2
2
2
Barnesiella viscericola
2
2
2
2
2
Bacteroides fragilis
Bacteroides fragilis
Bacteroides fragilis
Bacteroides fragilis
Bacteroides fragilis

Six percent (5/83) of BFSS isolates from BJH and 95% (19/20) of IHMA isolates had cﬁA
detected via AMRﬁnder in the WGS assemblies (Fig. 4); however, the respective contigs
were often immediately interrupted upstream of cﬁA. IS elements are known to interrupt
short-read assemblies due to the presence of redundant IS copies throughout the genome
(17). Thus, Oxford Nanopore long-read sequencing reads were generated to build hybrid
assemblies for all cﬁA-positive BFSS strains with contigs interrupted immediately upstream
of cﬁA (17/24). IS elements upstream of cﬁA within the hybrid assemblies were identiﬁed
with Prokka (19) which utilizes the ISﬁnder database (20). IS elements were identiﬁed
upstream of cﬁA in 12 BFSS genomic assemblies (Table 2), all of which were carbapenem-resistant according to both CLSI and EUCAST breakpoints. Most of the identiﬁed insertion
sequences were in the IS1380 family (21). The cﬁA-positive, carbapenem-resistant strain
IHMA_10 had no associated IS as detected by ISﬁnder. However, a nucleotide BLAST search
of the upstream region identiﬁed a transposase IS982 from Barnesiella viscericola, an obligate
anaerobic Gram-negative bacterium related to Parabacteroides distasonis (22), suggesting
cross-family transfer of IS elements.
The Bruker MALDI Biotyper Subtyping Module (MBT-S) is a novel MALDI-ToF application that enables rapid detection of speciﬁc bacterial resistance markers, including
CﬁA, at the same time during organism identiﬁcation in a streamlined workﬂow.
Following high-conﬁdence identiﬁcation of BFSS (i.e., a MALDI-TOF score $ 2.0), the
subtyping module looks for the presence of peaks associated with expression of the
CﬁA carbapenemase and may, thus, serve as an early warning system of carbapenemresistant BFSS isolates in clinical settings. We evaluated the accuracy of the MBT-S CﬁA
call-out with all BFSS isolates from both BJH and IHMA collections (n = 103) compared
to phenotypic resistance evaluated using CLSI and EUCAST breakpoints (Table 3 and
Table S1). Compared to ertapenem and meropenem resistance deﬁned by CLSI breakpoints, the MBT-S demonstrated positive percent agreement (PPA), negative percent
agreement (NPA) of 94%, 90%, and 95%, 95%, respectively. Using EUCAST interpretive
January/February 2022 Volume 13 Issue 1 e03603-21
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TABLE 3 Evaluation of Bruker MALDI Biotyer Subtyping module across IHMA and BJH B.
fragilis sensu stricto isolates (n = 103)
CLSI breakpoints
PPA (95% CI)
NPA (95% CI)
CA
VME
ME

Ertapenem
93.8 (67.7–99.7)
89.6 (80.1–94.9)
90.3% (93/103)
6.3% (1/16)
10.3% (9/87)

EUCAST breakpoints
Meropenem
95.2 (74.1–99.8)
95.1 (87.3–98.4)
95.1% (98/103)
4.8% (1/21)
4.9% (4/82)

Ertapenem
84 (63.1–94.7)
96.2 (88.4–99.0)
93.2% (96/103)
16.0% (4/25)
3.8% (3/78)

Meropenema
95.2 (74.1–99.8)
96.3 (88.8–99.0)
96.1% (99/103)
4.5% (1/22)
3.7% (3/81)

criteria, the MBT-S demonstrated PPA, NPA of 84%, 96% for ertapenem, and 95%, 96%
for meropenem, respectively. Among consecutively collected BFSS isolates from BJH
only, the positive predictive value (PPV) was 50% and negative predictive values (NPV)
ranged from 96 to 100% across all carbapenems and guidelines evaluated indicating
the need for conﬁrmatory testing of MBT-S CﬁA positive callouts but high-conﬁdence
in MBT-S CﬁA-negative callouts (Table S1). In settings of high rates of carbapenem resistance, PPV is expected to improve (Table S1). Category agreement (CA), very major
error (VME), and major error (ME) rates were also determined for the MBT-S CﬁA callout
compared to carbapenem susceptibility interpreted using CLSI and EUCAST breakpoints. CA was deﬁned as the proportion of total isolates with phenotypic susceptibility and MBT-S results in agreement (i.e., carbapenem susceptible/MBT-S CﬁA negative
or carbapenem non-susceptible/MBT-S CﬁA positive). CA compared to ertapenem and
meropenem susceptibility per CLSI was 90.3%, 95.1%, respectively, and 93.2%, 96.1%
using EUCAST breakpoints. Regardless of carbapenem or interpretive criteria, VME and
ME, deﬁned as the proportion of carbapenem non-susceptible testing CﬁA negative by
MBT-S and the proportion of carbapenem susceptible isolates testing positive for CﬁA
by MBT-S, respectively, exceeded 3.0% (Table 3).
Approximately half of the BFSS isolates from BJH (n = 38, 45%) and nearly all IHMA
isolates (n = 19, 95%) were positive for cﬁA by previously established PCR methods
(Data Set S1, Table 2) (18). An amplicon of a size consistent with cﬁA was also detected
among 47% of non-fragilis Bacteroides species (n = 43) which represented the majority
of B. ovatus (78%) and P. distasonis isolates. To our knowledge, this is the ﬁrst report of
cﬁA detection in non-fragilis-BFG. However, the AMRﬁnder tool did not detect any
genes annotated as cﬁA within these strains. Of the cﬁA-PCR positive BFSS isolates,
2.4% (2/83) from BJH and 47.4% (9/19) from IHMA had an amplicon consistent with an
upstream IS, while none of the non-fragilis BFG had cﬁA-associated IS elements
detected by PCR. Among carbapenem-resistant BFSS, 52% (11/21) were positive for
both cﬁA and an upstream IS by PCR. All IS PCR positive isolates (n = 11) were conﬁrmed by ISﬁnder or BLAST, with one additional isolate with a full-length IS sequence
(IHMA_16) identiﬁed genomically. The forward primer binding sites (23) could not be
found in the regions surrounding the IS element, which likely explains the negative
PCR result. PCR-based methods for cﬁA-associated IS detection appear accurate in
comparison to other methods, while cﬁA PCR frequently yielded several positive strains
that were not validated by WGS or MBT-S (Data Set S1, Table 2).
Across the entire isolate cohort, IHMA_8 was the only carbapenem-resistant BFSS isolate with no detectable cﬁA across all methods tested (Table 2). This isolate, IHMA_8, had
MICs of 16 and .32 m g/mL to ertapenem and meropenem, respectively. Intriguingly, carbapenem resistance in this strain appears to be independent of IS activation of CﬁA or the
presence of the cﬁA gene entirely. In addition to resolving cﬁA-associated ISs, hybrid genome assembly allowed for complete resolution of a 14.6 kbp plasmid harboring the
HMM-identiﬁed multispecies class A b -lactamase (bla) gene in IHMA_8 (Fig. S5A). The
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Abbreviations: PPA, positive percent agreement; NPA, negative percent agreement; CI, conﬁdence interval; CA,
category agreement; VME, very major error rate; ME, major error rate.
aTotal n = 102, excludes 1 IHMA isolate with meropenem MIC = 4 (EUCAST meropenem breakpoints: susceptible
#2, resistant .8).
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genomic architecture surrounding the bla gene was conserved among several isolates and
had the structure of a mobilizable transposon (Fig. S5B) (24, 25). Unique to IHMA_8, however, an IS was apparent upstream of the bla gene, which could contribute to the elevated
resistance to all b -lactams tested in this study (Fig. S5B).
Division I and II B. fragilis SS isolates fall into distinct genomospecies categorizations.
Previous studies have revealed that BFSS isolates segregate into two divisions which
are distinguished by the mutually exclusive presence of endogenous cepA (division I)
or cﬁA (division II) (11). Our investigations further revealed that division II isolates
appear to be distinct genomospecies due to phylogenetic clustering (Fig. 2A) and ANI
values below the threshold for species-level identiﬁcation with type BFSS strains
(Fig. 2C). A genome alignment of the division I reference genome from NCTC 9343 and
the division II isolate IHMA_4, which had a closed, circular genome through hybrid assembly, revealed that cepA and cﬁA are present in distinct regions of the genome
(Fig. S6). To further compare division I and division II strains, all available BFSS assemblies from NCBI as well as isolate assemblies from this study were used to generate a
core genome alignment and an unrooted, maximum likelihood BFSS phylogeny tree
(Fig. 5A). All division I and division II strains again formed two distinct clades. Type
assemblies, most BJH assemblies, and the representative commensal genomes were in
the division I clade, while most IHMA strains and the ﬁve cﬁA-positive BJH strains were
division II. Guanine-cytosine (GC) content, as well as genome length values generated
from the assemblies, were not signiﬁcantly different between the two divisions
(Unpaired t test, GC content: P = 0.06, genome length: P = 0.78) (Fig. 5B). Closer inspection of pairwise ANI and AAI values of the complete BFSS genome collection revealed
distinct clustering for both values that was stratiﬁed by division status, with division II
ANI values well below the species cutoff of 95% relative to all division I strains (Fig. 5C)
(12). Finally, a principal-component analysis revealed much of the variance within the
accessory genome is due to division I or II status, as these two divisions clustered
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FIG 5 Comparative genomic analyses between division I and division II BFSS. (A) Unrooted, maximum likelihood phylogenetic tree generated from a core
genome alignment of all BFSS strains in this study as well as available assemblies from NCBI. (B) GC content and genome lengths were compared between
the two BFSS divisions. The difference between the means for both GC content and length was not statistically signiﬁcant as determined by an unpaired
two-tailed t test (Prism v9.0.0). (C) Pairwise average nucleotide identity (ANI) and average amino acid identity (AAI) of BFSS genomes. Data are stratiﬁed on
the x-axis by division of the ﬁrst isolate within the isolated pair and data points are colored by division status of the corresponding division of the partner
isolate (dark blue = division I, light blue = division II) (D) Principal-component analysis (PCA) based on Jaccard distance matrix of the accessory genome of
BFSS strains and scree plot of principal coordinate eigenvalues.
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DISCUSSION
Anaerobic bacteria can cause life-threatening infections and present unique challenges
in terms of antimicrobial resistance, yet species-level identiﬁcation and susceptibility testing
are not routinely performed in many clinical labs. Previous studies demonstrate BFG species
are the most frequent cause of anaerobic infection (2), yet comprehensive characterization
from a phenotypic, diagnostic, and genomic perspective has not been recently reported on
contemporary isolates. Within this study, we establish the crucial link between species and
resistance proﬁles to frontline antibiotics. MALDI-ToF identiﬁcation of BFG isolates to species-level were veriﬁed with a phylogenetic analysis of WGS assemblies. Although most species within BFG (B. fragilis, B. vulgatus, B. ovatus, B. thetaiotaomicron, B. caccae, and B. pyogenes) are claimed indications of both FDA-cleared MALDI-ToF platforms for microorganism
identiﬁcation, some laboratories report these organisms to the group level. Our ﬁndings
indicate that MALDI-ToF-based species-level identiﬁcations are not only reliable but may
also be clinically informative as distinct resistance proﬁles between members of the BFG
were observed. Elevated MICs among non-fragilis Bacteroides spp. to piperacillin-tazobactam
compared to mostly susceptible BFSS isolates was most profound (Fig. 3 and Table 1). These
ﬁndings are consistent with previous reports of national anaerobic antimicrobial susceptibility surveys (6, 8). Furthermore, the frequency of each unique BFG species as well as the variety of infection sites in our local BJH collection is reﬂective of previous reports (2, 8, 9),
strengthening the ability to translate these ﬁndings to cohorts in other locations.
Despite growing evidence of stark differences in resistance patterns against both b -lactam/b -lactamase inhibitor combination agents and carbapenems between BFSS and nonfragilis Bacteroides species and congruent enrichment of speciﬁc b -lactamases, the mechanistic basis of species-dependent resistance has not been entirely explained. This raises
multiple questions worth further study. Alterations in the penicillin-binding protein (PBP) target or modiﬁcations that promote efﬂux or alter cell permeability to confer b -lactam resistance, for example, may be alternative mechanisms worth comprehensively exploring in BFG
(26, 27). We determined there were at least eight distinct PBPs and 10 porins in the BFSS isolates in this study using a BLASTP search (Fig. S3B and C). Additional copies of PBP2xBfr and
PBP4Bfr were noted in BJH_7 and BJH_108, respectively, while PBP2Bfr was missing in
IHMA_15. IHMA_15, which was meropenem resistant and had reduced ertapenem susceptibility, was the only strain exhibiting loss of a porin coding region. Among division I strains,
BJH_108 had an elevated piperacillin-tazobactam MIC (2 m g/mL, BFSS MIC50 = 1 m g/mL).
The BLASTP identities for division II BFSS were found to vary substantially for most of the
PBPs while identities below 90% were generally only observed for two porins in this division
(Fig. S3D and E). Although PBP and porin populations of BFSS are moderately deﬁned in the
literature, further studies are needed to conﬁrm the potential effects of speciﬁc resistance
mutations or gene loss on b -lactam susceptibility.
A MALDI-ToF application validated in this study is the detection of CﬁA for early warning resistance prediction in BFSS isolates by the Bruker Subtyper module (MBT-S). Because
anaerobic susceptibility testing is not often performed in most clinical laboratories, clinical
resistance is likely underreported. Herein we report that the MBT-S demonstrated 94 to
95% PPA and 90 to 95% NPA compared to carbapenem susceptibly interpreted by CLSI
guidelines (Table 3). Among consecutively collected BFSS isolates from BJH only, this
resulted in a PPV of 50% and NPV ranging from 96 to 100%. Category agreement compared to carbapenem susceptibly was also $ 90%. These data suggest that the Bruker
MBT-S is most useful as a carbapenem resistance rule-out in BFSS isolates routinely in clinical labs. Importantly, presumptive CﬁA detection by MBT-S did not always correspond to
phenotypic carbapenem resistance as evidenced by VME and ME rates . 3%, unacceptable by the FDA for new antimicrobial susceptibility test systems. As such, MBT-S CﬁA
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distinctly across the PC1 axis (PC1 = 19.17% variance explained) (Fig. 5D). Altogether,
division II BFSS, which accounts for most of the resistance to the last resort agent carbapenem in BFG, is genetically distinct from division I and is, by accepted metrics (12),
a distinct genomospecies.

detection should be followed-up with additional testing to conﬁrm carbapenemase-mediated resistance particularly in settings with carbapenem-resistant BFSS rates of , 1%
where the MBT-S PPV is expected to be ,50% (Table S1). Modiﬁcations of widely utilized
rapid phenotypic carbapenemase assays, such as the mCIM or Carba-NP may be effective
strategies to conﬁrm MBT-S presumptive CﬁA detections readily in the clinical lab.
Nonetheless, MALDI-ToF MS appears to be a powerful tool that can yield important
insights into the possible resistance of this diverse organism group.
Although most carbapenem resistance in BFSS is thought to be cﬁA-mediated, cﬁA-independent resistance has also been reported. In this cohort, IHMA_8 had high-level resistance
to ertapenem (MIC = 16), meropenem ($32), and piperacillin-tazobactam ($256). However,
PCR and WGS-based methods failed to detect a cﬁA gene or IS element. IHMA_8 encoded
cepA classifying it within division I BFSS isolates that are rarely carbapenem-resistant.
Division I strains with elevated resistance to carbapenems and piperacillin-tazobactam often
had other b -lactam ARG classes in addition to cepA, including IHMA_8 which had a mobilized class A bla gene identiﬁed by HMM proﬁling that was located downstream of an IS element (Fig. S5). Several bla genes were identiﬁed in our BFG isolate collection through HMM,
but these genes do not appear to have been previously characterized or annotated in resistance gene databases. Additional studies characterizing the activity and spectrum of these
putative b -lactamases in anaerobic bacteria are warranted.
In non-fragilis Bacteroides species, much less is known about the mechanism of carbapenem resistance. Detection of cﬁA has not been described in these species but we found that
nearly half of non-fragilis Bacteroides species in our isolate cohort had amplicons consistent
with a cﬁA PCR product (Data set S1). However, we were unable to detect genes annotated
as cﬁA in genomic assemblies or analysis of raw (preassembly) Illumina short-read sequencing reads in PCR positive non-fragilis Bacteroides isolates. While PCR artifact or contamination
cannot be excluded, additional studies investigating the potential for distant cﬁA homologs,
interrupted pseudogenes, or cﬁA regions that are not captured in the conventional shortread assembly process are needed to verify this ﬁnding.
Interestingly, we found that phenotypic resistance proﬁles were not always interpreted
consistently when different breakpoints (CLSI or EUCAST) were applied. For example, across
all species, decreased susceptibility to piperacillin-tazobactam and carbapenems was
observed when using EUCAST versus CLSI interpretive criteria due to a lower susceptible
breakpoint for ertapenem (#0.5 m g/mL per EUCAST versus #4 m g/mL per CLSI), meropenem (#2 m g/mL per EUCAST versus #4 m g/mL per CLSI), and piperacillin-tazobactam (#8
per EUCAST versus #16 per CLSI) (Table 1). Additional studies evaluating clinical outcomes
and MIC distributions of various species within the BFG are needed to determine whether
species-level reporting and clinical breakpoints are warranted.
Among BFSS isolates, we uncovered a striking genetic divergence between division
I and division II species, which is for the ﬁrst time described through comparative
genomics methods in this study. The CﬁA carbapenemase is only present in division II
strains, yet all reported type assemblies and many commensal BFSS genomes (16) are
division I strains. The source of anaerobic infection is often commensal microbes (2),
which begs the question of whether division II BFSS can exist as a commensal, serving
as a reservoir for highly resistant infections.
We note important limitations to our study. Most isolates studied (174/194) were from a
single medical center, so the translation of these results where BFG resistance rates vary by
geographic region is unclear. Furthermore, information on clinical treatment outcomes and
the impact of rapid presumptive cﬁA detection were not evaluated. Nevertheless, we report
the largest comparative genomic analysis of a BFG cohort to date, which can serve as a basis
for future comparisons to data sets from other regions. Paired with robust clinical data sets
on the source, diagnosis, and phenotypic resistance proﬁles, these ﬁndings inform our
understanding and management of BFG infection.
In summary, we present a comprehensive study of 194 BFG isolates, which are a dominant cause of anaerobic infection. We leveraged comparative genomics to conﬁrm the accuracy of two widely used MALDI-ToF MS technologies in resolving species-level identities
January/February 2022 Volume 13 Issue 1 e03603-21

mbio.asm.org

12

Downloaded from https://journals.asm.org/journal/mbio on 24 May 2022 by 128.252.212.229.

®

Wallace and Jean et al.

®

Comparative Genomics of BFG Clinical Isolates

and cﬁA prediction, the importance of which is emphasized by our ﬁndings of striking species-dependent phenotypic and ARG proﬁles to commonly administered antibiotic agents.
We report cﬁA/IS-dependent and independent mechanism of activating resistance to carbapenems in this cohort and validate multiple tools for cﬁA and IS detection. Finally, our
data assert division II BFSS, which is identiﬁed at high frequency in carbapenem-resistant
BFG infections, as a distinct genomospecies from division I BFSS.

Clinical study isolates and MALDI-ToF MS analysis. A total of 174 Bacteroides fragilis group (BFG)
consecutively available isolates recovered from clinical specimens submitted to the Barnes Jewish
Hospital clinical microbiology laboratory (St. Louis, MO) from February 2018 to July 2018 were evaluated
in this study. To increase the number of carbapenem-resistant BFG evaluated, 20 BFSS isolates resistant
to a carbapenem class agent were acquired from the International Health Management Associates
(IHMA) bacterial repository for evaluation, and cﬁA-positive BFSS isolates obtained from the BarnesJewish clinical lab collected through 2020 were also included. Isolates were subcultured on prereduced
anaerobically sterile (PRAS) Brucella (Hardy Diagnostics) and incubated in anaerobic conditions for species-level identiﬁcation with 2 commercial matrix-assisted laser desorption ionization-time of ﬂight mass
spectrometry (MALDI-ToF MS) systems: MALDI Biotyper (Bruker Daltonics) Research Use Only (RUO)
Database BDALv7 and VITEK-MS (bioMérieux) RUO Knowledge Base v. KB 3.0 per manufacturer’s instructions. For cﬁA detection, the Bruker MBT Subtyper module was enabled and simultaneously used during
spectra acquisition for isolate identiﬁcation. Isolates identiﬁed as B. fragilis sensu stricto (BFSS) with a
high conﬁdence score (.2.0) received a presumptive cﬁA positive or negative determination.
Anaerobic antimicrobial susceptibility testing. Clinical BFG isolates were evaluated by gradient
diffusion method for susceptibility to antimicrobial agents piperacillin-tazobactam (LioﬁlChem), ertapenem, meropenem, and metronidazole (bioMérieux). BFG isolates cultured on PRAS Brucella blood agar
for 24 to 28 h were used to make 1 McFarland standard organism suspension in Brucella broth (BD
BBLTM) which was then lawn-struck onto PRAS Brucella blood agar plates. Gradient diffusion strips were
placed on inoculated plates and incubated at 35°C in EZ Anaerobe Gas-pack systems (BD) for up to 72 h.
MICs were read at 72h. Species-speciﬁc differences in MIC were investigated using Tukey’s multiple-comparison test with ordinary one-way ANOVA (GraphPad Prism v9.0.0) to detect signiﬁcant differences
between the geometric mean of each species group (deﬁned as an adjusted P value ,0.05).
Genomic DNA extraction and molecular detection of carbapenemase genetic determinants cﬁA
and IS. BFG isolates stored at 280°C were cultured onto Brucella blood agar and grown in anaerobic conditions for 48 h at 35°C. Fresh (,72 h) BFG isolates from Brucella blood agar incubated anaerobically were harvested and resuspended in nuclease-free, molecular grade water and frozen at 220°C until DNA extraction.
Genomic DNA was extracted from each isolate using the QIAamp/MoBio BiOstic Bacteremia DNA kit (Qiagen).
End-point PCR was used to detect cﬁA and upstream insertions sequence elements (IS) from all BFG
isolates using previously described methods (23). Brieﬂy, illustraTM puRe Taq Ready-to-Go PCR beads (GE
Healthcare, UK) were suspended with a master mix containing 100 ng of gDNA, forward (GBI-1, 59CCCAACTCTCGGACAAAGTG) and reverse (GBI-2, 59-AGTGAATCGGTGAATCCATG) primers at a ﬁnal concentration of 0.2 m M and sterile nuclease-free water up to a ﬁnal volume of 25 m L. For cﬁA PCR the reaction was performed under the following conditions: 95°C for 5 min for initial denaturation, then 35
cycles of 95°C for 20 sec, 64°C for 2 min, 72°C for 30 sec, followed by a 5 min ﬁnal extension at 74°C. For
IS PCR, Ready-to-Go PCR beads were suspended with a master mix as described above with IS forward
(G, 59-CGCCAAGCTTTGCCTGCCATTAT) and reverse (E, 59-CTTCGAATTCGGCGAGGGATACATAA) primers
(18). Following an initial denaturation of 95°C for 5 min, the reaction was cycled 35 times at 95°C for
20 sec, 64°C for 2 min, 74°C for 3 min, followed by a ﬁnal extension of 74°C for 5 min. PCR amplicons
were visualized on a 2% agarose gel. Expected amplicon sizes were 350 bp for cﬁA PCR and1.6 to 1.7Kb
for IS PCR. Each PCR batch was run with positive (cﬁA1/IS1: WIS-ImiR-001, cﬁA1/IS-: B. fragilis ATCC
25285TM), negative (cﬁA-/IS-: B. thetaiotaomicron ATCC 29741TM) and no template controls that performed as expected on all valid runs.
Whole-genome sequencing and de novo genome assembly. For whole-genome sequencing, 0.5 ng
gDNA for each isolate was used to prepare Illumina sequencing libraries using the Nextera kit (Illumina, San
Diego, CA, USA) (28). All libraries were pooled at equal concentrations and sequenced at a target depth of 2 million reads per sample (2  150 bp) on the NextSeq 500 High Output platform (Illumina, San Diego, CA, USA).
Adapters were removed from the demultiplexed reads via Trimmomatic (v0.38) (29), and read qualities
were assessed using FastQC (v0.11.7) (29). Genome assemblies were built using Unicycler (v0.4.7) (30), and assembly quality was evaluated using Quast (v4.5). De novo assemblies were sequenced at $40 sequencing
depth with a total number of contigs #300 and N50 $10,000 were selected for further analyses. In some
cases, additional reads were obtained to achieve at least 40 coverage. Completeness and contamination
were evaluated using CheckM (v1.0.13) (31) to ensure completeness values $95% and contamination #5%.
Prokka (v1.14.5, default parameters, contigs .500 bp) (19) was used to annotate high-quality genomes.
Hybrid genome assembly. Select strains underwent Oxford Nanopore long-read sequencing and
hybrid assembly (BJH_13, BJH_14, BJH_140, BJH_141, IHMA_1, IHMA_2, IHMA_3, IHMA_4, IHMA_6,
IHMA_8, IHMA_9, IHMA_10, IHMA_13, IHMA_16, IHMA_17, IHMA_18, IHMA_19, IHMA_20). BFG cells
were cultivated and harvested as described previously and stored at 280°C. High molecular weight DNA
was extracted using the phenol-chloroform extraction method, and the gDNA was stored at 4°C for up
to 1 week. Libraries were prepared using the Oxford Nanopore Ligation Sequencing and Native Barcode
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kits. Filtlong was used to subsample the long reads to 100 sequencing depth. Unicycler (30) was
employed for hybrid assemblies of each genome using both long reads and Illumina short reads.
As required for BJH_14, manual ﬁnishing of the IS-cﬁA region was carried out using minimap2
(v2.14) and samtools (v1.9). Long reads with a minimum length of 2000 nucleotides that aligned with
the putative IS-cﬁA query sequence with 85% identity over a minimum of 1000 nucleotides were
extracted and aligned with the query sequence. This resulted in 185 reads extracted and aligned with a
mean depth of coverage of 144 over the IS-cﬁA query sequence (samtools v1.12).
Comparative analyses. Roary v3.12.0 (32) was used for core genome alignments of de novo short-read
assemblies and deposited assemblies, with a BLASTP cutoff of 70 for alignment of the entire BJH isolate collection with Type assemblies and a BLASTP cutoff of 90 for the B. fragilis SS alignment. Neighbor-joining phylogenetic trees were constructed from these alignments using FastTree v2.1.7. ANI values were determined
using pyANI (https://github.com/widdowquinn/pyani). The maximum-likelihood tree for Fig. 5 was constructed from the B. fragilis SS alignment using raxml v8.2.11 (GTRGAMMA model, 1,000 bootstraps). GC content and genome lengths were compared using an unpaired two-tailed t test (Prism v9.0.0). PCA of accessory
genomes was performed using the Vegan package of R functions (33) with accessory genes identiﬁed from
the Roary output for the B. fragilis SS core genome alignment as input.
ARG and associated insertion sequence identiﬁcation. AMRﬁnder (v3.8.4) was employed to detect
ARGs. For the detection of PBPs and porins, protein BLAST was carried out using BLAST1 (v2.9.0) using
an E value cutoff of 110220 and a percentage identity cutoff of 50%. Insertion sequences were identiﬁed upstream of the cﬁA gene in Division II BFSS genomes using the built-in ISFinder function of Prokka
as well as the ISFinder BLAST tool to generate additional IS sequence characterization for Table 2 (20).
Data Availability. Raw sequencing data and whole-genome assemblies are available under
BioProject ID PRJNA745162.
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